GURUFOCUS.COM » STOCK LIST » Technology » Software » Firefly Neuroscience Inc (NAS:AIFF) » Definitions » Treasury Stock

AIFF (Firefly Neuroscience) Treasury Stock : $0.00 Mil (As of Sep. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Firefly Neuroscience Treasury Stock?

Treasury stock is the portion of shares that a company keeps in their own treasury. Firefly Neuroscience's treasury stock for the quarter that ended in Sep. 2024 was $0.00 Mil.

Treasury stock may have come from a repurchase or buyback from shareholders; or it may have never been issued to the public in the first place.


Firefly Neuroscience Treasury Stock Historical Data

The historical data trend for Firefly Neuroscience's Treasury Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Firefly Neuroscience Treasury Stock Chart

Firefly Neuroscience Annual Data
Trend Dec21 Dec22
Treasury Stock
- -

Firefly Neuroscience Quarterly Data
Dec21 Sep22 Dec22 Jun23 Sep23 Jun24 Sep24
Treasury Stock Get a 7-Day Free Trial - - - -0.97 -

Firefly Neuroscience Treasury Stock Calculation

The portion of shares that a company keeps in their own treasury. Treasury stock may have come from a repurchase or buyback from shareholders; or it may have never been issued to the public in the first place. These shares don't pay dividends, have no voting rights, and should not be included in shares outstanding calculations.


Firefly Neuroscience Business Description

Traded in Other Exchanges
N/A
Address
1100 Military Road, Kenmore, NY, USA, 14217
Firefly Neuroscience Inc is an AI company developing neuroscientific solutions that improve outcomes for patients with mental illnesses and cognitive disorders. It is focused on the commercialization of its Brain Network Analytics (BNA) software platform (the "BNA Platform")and the discovery and clinical development of biomarkers that support outcomes for people suffering from mental illnesses and cognitive disorders.